Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 52
Filter
1.
Hum Immunol ; 81(4): 168-177, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32081570

ABSTRACT

HLA-G was described as a molecule inhibiting NK and T cells functions through its receptor, ILT2. However, most functional studies of HLA-G were so far performed on heterogeneous immune populations and regardless of ILT2 expression. This may lead to an underestimation of the effect of HLA-G. Thus, considering the immune subpopulations sensitive to HLA-G remained an important issue in the field. Here we present a new cytometry assay to evaluate HLA-G effects on both NK and CD8+ T cell cytotoxic functions. Using flow cytometry allows for the comparison of HLA-G function on multiple subsets and multiple functions in the same time. In particular, we sharpen the analysis by specifically studying the immune subpopulations expressing HLA-G receptor ILT2. We focused our work on: IFN-gamma production and cytotoxicity (CD107a expression) by CD8+ T cells and NK cells expressing or not ILT2. We compared the expression of these markers in presence of target cells, expressing or not HLA-G1, and added a blocking antibody to reverse HLA-G inhibition. This new method allows for the discrimination of cell subsets responding and non-responding to HLA-G1 in one tube. We confirm that HLA-G-specifically inhibits the ILT2+ CD8+ T cell and ILT2+ NK cell subsets but not ILT2-negative ones. By blocking HLA-G/ILT2 interaction using an anti-ILT2 antibody we restored the cytotoxicity level, corroborating the specific inhibition of HLA-G1. We believe that our methodology enables to investigate HLA-G immune functions easily and finely towards other immune cell lineages or expressing other receptors, and might be applied in several pathological contexts, such as cancer and transplantation.


Subject(s)
Antigens, CD/metabolism , Flow Cytometry/methods , HLA-G Antigens/immunology , Leukocyte Immunoglobulin-like Receptor B1/metabolism , Antibodies, Blocking/immunology , CD57 Antigens/metabolism , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Cytotoxicity, Immunologic , Humans , K562 Cells , Killer Cells, Natural/immunology , Killer Cells, Natural/metabolism , Leukocyte Immunoglobulin-like Receptor B1/antagonists & inhibitors , Lymphocyte Subsets/immunology , Lymphocyte Subsets/metabolism , THP-1 Cells
2.
Am J Transplant ; 15(2): 461-71, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25488753

ABSTRACT

Human leukocyte antigen G (HLA-G) expression is thought to be associated with a tolerance state following solid organ transplantation. In a lung transplant (LTx) recipient cohort, we assessed (1) the role of HLA-G expression as a predictor of graft acceptance, and (2) the relationship between (i) graft and peripheral HLA-G expression, (ii) HLA-G expression and humoral immunity and (iii) HLA-G expression and lung microenvironment. We prospectively enrolled 63 LTx recipients (median follow-up 3.26 years [min: 0.44-max: 5.03]). At 3 and 12 months post-LTx, we analyzed graft HLA-G expression by immunohistochemistry, plasma soluble HLA-G (sHLA-G) level by enzyme-linked immunosorbent assay, bronchoalveolar lavage fluid (BALF) levels of cytokines involved in chronic lung allograft dysfunction (CLAD) and anti-HLA antibodies (Abs) in serum. In a time-dependent Cox model, lung HLA-G expression had a protective effect on CLAD occurrence (hazard ratio: 0.13 [0.03-0.58]; p = 0.008). The same results were found when computing 3-month and 1-year conditional freedom from CLAD (p = 0.03 and 0.04, respectively [log-rank test]). Presence of anti-HLA Abs was inversely associated with graft HLA-G expression (p = 0.02). Increased BALF level of transforming growth factor-ß was associated with high plasma sHLA-G level (p = 0.02). In conclusion, early graft HLA-G expression in LTx recipients with a stable condition was associated with graft acceptance in the long term.


Subject(s)
Graft Rejection/blood , Graft Rejection/epidemiology , HLA-G Antigens/blood , Lung Transplantation , Transplant Recipients , Adult , Biomarkers/blood , Bronchoalveolar Lavage Fluid/chemistry , Cohort Studies , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Risk Factors , Time Factors , Transforming Growth Factor beta/analysis
3.
Am J Transplant ; 14(5): 1173-82, 2014 May.
Article in English | MEDLINE | ID: mdl-24730563

ABSTRACT

Phase III clinical studies have shown that kidney transplant (KT) recipients treated with the costimulation blocker belatacept exhibited a better renal allograft function and lower donor-specific anti-HLA immunization when compared to recipients treated with calcineurin inhibitors (CNI). We analyzed B cell phenotype in KT recipients treated with belatacept and stable renal function (N = 13). Results were compared to those observed in stable patients treated with CNI (N = 12), or with chronic antibody-mediated rejection (N = 5). Both transcriptional profile and phenotypic characterization of peripheral B cells were performed by real-time polymerase chain reaction and flow cytometry, respectively. In belatacept group, the frequency and absolute number of transitional B cells as defined by both phenotypes: CD19(+) CD24(hi) CD38(hi) and CD19(+) IgD(hi) CD38(hi) CD27(-) , as well as naïve B cells were significantly higher compared with CNI group. B cell activating factor (BAFF) and BAFF receptor mRNA levels were significantly lower in belatacept group than in CNI group. These results show for the first time that belatacept influences B cell compartment by favoring the occurrence of transitional B cells with potential regulatory properties, as described in operational tolerant patients. This role may explain the lower alloimmunization rate observed in belatacept-treated patients.


Subject(s)
Graft Rejection/drug therapy , Immunoconjugates/therapeutic use , Immunosuppressive Agents/therapeutic use , Kidney Failure, Chronic/surgery , Kidney Transplantation , Precursor Cells, B-Lymphoid/cytology , Transplant Recipients , Abatacept , B-Cell Activating Factor/genetics , B-Cell Activating Factor/metabolism , B-Cell Activation Factor Receptor/genetics , B-Cell Activation Factor Receptor/metabolism , Cells, Cultured , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Cohort Studies , Female , Flow Cytometry , Follow-Up Studies , Graft Rejection/immunology , Graft Rejection/metabolism , Humans , Male , Middle Aged , Precursor Cells, B-Lymphoid/metabolism , Prognosis , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction
4.
Tissue Antigens ; 82(1): 53-8, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23745572

ABSTRACT

Host and Plasmodium interactions result in highly variable clinical phenotypes, partly explained by the nature and level of anti-malarial antibody response. Human leukocyte antigen (HLA)-G can create a tolerogenic environment, allowing parasites to escape from anti-malarial immunity. We performed a family-based association study encompassing 483 Sereer individuals (261 children and their parents), and reported two independent signals at the HLA-G 3' untranslated region associated with antibody response to specific Plasmodium falciparum blood stage antigens, previously associated with malaria protection: (i) +3010G together with +3142C with total IgG and IgG1 against GLURP and (ii) +3196G with IgG3 against MSP2. While these results require further investigation, they suggest for the first time a role of HLA-G in the regulation of humoral immune response in malaria.


Subject(s)
3' Untranslated Regions/genetics , Antibody Formation/immunology , Antigens, Protozoan/immunology , Genetic Association Studies , HLA-G Antigens/genetics , Plasmodium falciparum/immunology , Polymorphism, Genetic , Adolescent , Child , Child, Preschool , Haplotypes/genetics , Humans , Linkage Disequilibrium/genetics , Malaria, Falciparum/immunology , Senegal
6.
J Viral Hepat ; 18(2): 102-5, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20236238

ABSTRACT

As the mechanisms leading to the persistence of hepatitis B virus (HBV) infection are poorly understood and as the histocompatibility leucocyte antigen (HLA)-G is well described as a tolerogenic molecule, we evaluated HLA-G expression in 74 specimens of HBV liver biopsies and in 10 specimens obtained from previously healthy cadaver liver donors. HBV specimens were reviewed and classified by the METAVIR score, and HLA-G expression was assessed by immunohistochemistry. No HLA-G expression was observed in control hepatocytes. In contrast, 57 (77%) of 74 HBV specimens showed soluble and membrane-bound HLA-G expression in hepatocytes, biliary epithelial cells or both. No associations between the intensity of HLA-G expression and patient age or gender, HBeAg status, severity of liver fibrosis, and grade of histological findings were observed. Although significance was not reached (P = 0.180), patients exhibiting HLA-G expression presented a higher median HBV DNA viral load (105 copies/mL) than those who did not express HLA-G (10(3.7) copies/mL). These results indicate that HLA-G is expressed in most cases of chronic HBV infection in all stages and may play a role in the persistency of HBV infection.


Subject(s)
HLA Antigens/biosynthesis , HLA Antigens/immunology , Hepatitis B virus/immunology , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/pathology , Histocompatibility Antigens Class I/biosynthesis , Histocompatibility Antigens Class I/immunology , Liver/immunology , Liver/pathology , Adolescent , Adult , Biopsy , Epithelial Cells/chemistry , Female , Gene Expression , HLA-G Antigens , Hepatocytes/chemistry , Humans , Immunohistochemistry , Male , Microscopy , Middle Aged , Severity of Illness Index , Young Adult
7.
Tissue Antigens ; 75(3): 201-6, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20047640

ABSTRACT

The human leukocyte antigen (HLA)-G non-classical major histocompatibility complex (MHC) class I molecule was originally described in first-trimester trophoblasts at the fetal-maternal interface in 1990. Eight years later, the First International Conference on this molecule was inaugurated by Prof Jean Dausset, recipient of the Nobel Prize in Medicine. The Fifth International Conference on HLA-G, held in Paris on July 2009, began with a tribute to Prof Jean Dausset who left us recently. This conference was co-chaired by Dr Edgardo D. Carosella and Prof Hans Grosse-Wilde, included 57 oral presentations and was attended by approximately 140 delegates from 16 countries. We summarize here the major advances on the HLA-G molecule that were reported, including findings on its biological activity and characterization of new mechanisms of action, notably through mesenchymal stem cells and regulatory cells, and the previously unexplored role of HLA-G on immune cells such as gammadelta T-cells and B lymphocytes. Furthermore, the role of HLA-G during pregnancy was revisited and its impact in pathologies such as cancer, autoimmune disorders and transplantation was further extended.


Subject(s)
HLA Antigens/immunology , Histocompatibility Antigens Class I/immunology , Major Histocompatibility Complex/immunology , Autoimmune Diseases/genetics , Autoimmune Diseases/immunology , B-Lymphocytes/immunology , Female , Fetus/immunology , HLA Antigens/genetics , HLA-G Antigens , Histocompatibility Antigens Class I/genetics , Humans , Leukocytes/immunology , Major Histocompatibility Complex/genetics , Pregnancy/immunology , Pregnancy Trimester, First/genetics , Pregnancy Trimester, First/immunology , Trophoblasts/immunology
8.
Am J Transplant ; 9(6): 1427-38, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19656137

ABSTRACT

Human leukocyte antigen-G (HLA-G), a nonclassical HLA class I protein, promotes immune tolerance of solid-organ allografts, yet its role in lung transplantation (LTx) is unknown. We examined the expression of HLA-G in lung allografts through immunohistochemistry by a cross-sectional study of 64 LTx recipients, classified into four groups (stable patients, acute rejection [AR], bronchiolitis obliterans syndrome [BOS] and symptomatic viral shedders). A marked expression of HLA-G in bronchial epithelial cells (BEC) was frequently observed in stable recipients (n = 18/35 [51%]), but not in patients with AR (n = 14) or with BOS (n = 8). HLA-G was also expressed by 4 of 7 symptomatic viral shedders. In addition, HLA-G-positive patients from the stable group (n = 35) experienced lower incidence of resistant AR and/or BOS during long-term follow-up, as compared with their HLA-G-negative counterparts. Finally, in vitro data showed that interferon-gamma, a cytokine present in lung allograft microenvironment, upregulated HLA-G mRNA and protein expression in primary cultured human BEC. We conclude that HLA-G expression in the bronchial epithelium of lung allograft is elevated in some LTx recipients in association with their functional stability, suggesting a potential role of HLA-G as a tolerance marker.


Subject(s)
HLA Antigens/biosynthesis , Histocompatibility Antigens Class I/biosynthesis , Adult , Bronchi/metabolism , Bronchiolitis Obliterans/immunology , Cross-Sectional Studies , Female , Graft Rejection/immunology , HLA-G Antigens , Humans , Immunohistochemistry , Lung/virology , Lung Transplantation/immunology , Male , Middle Aged , Respiratory Mucosa/metabolism , Retrospective Studies , Virus Diseases/immunology
9.
Leukemia ; 22(5): 998-1006, 2008 May.
Article in English | MEDLINE | ID: mdl-18288133

ABSTRACT

Exploiting the antitumor effect of natural killer (NK) cells has regained interest in light of data from preclinical and clinical work on the potential of alloreactive NK cells. Multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) represent the two most prevalent adult hematological malignancies in the western hemisphere. To evaluate the role of NK cells in the immune surveillance and their therapeutic potential for CLL and MM, tumor cell susceptibility to NK-mediated killing was investigated. Results show relative resistance of tumor cells from CLL as well as MM (73 and 70% of the patients, respectively) to NK-mediated killing. To gain insight into molecular mechanisms of this resistance, the expression of the tolerogenic HLA-G molecule in CLL and MM and its relevance to susceptibility to NK-mediated killing were investigated. HLA-G transcript was found in tumor cells from 89% (n=19) of CLL and 100% (n=9) of MM patients examined. HLA-G1 surface expression was observed in CLL and was very low or undetectable in MM. Notably, blocking of HLA-G1 with specific antibody on CLL samples increased their susceptibility to NK-mediated killing, demonstrating that HLA-G participates in protecting CLL cells from NK-mediated killing and may thus contribute to their immune escape in vivo.


Subject(s)
HLA Antigens/immunology , Histocompatibility Antigens Class I/immunology , Killer Cells, Natural/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Multiple Myeloma/immunology , Tumor Escape , Antigens, Neoplasm , Cytotoxicity, Immunologic , HLA Antigens/analysis , HLA Antigens/genetics , HLA-G Antigens , Histocompatibility Antigens Class I/analysis , Histocompatibility Antigens Class I/genetics , Humans , Immunologic Surveillance , RNA, Neoplasm/analysis
10.
Leukemia ; 22(3): 578-84, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18059484

ABSTRACT

HLA-G5 is secreted by erythroblasts in all hematopoietic organs, suggesting a role for this protein in erythropoiesis. To examine this, we analyzed whether HLA-G5 affects the proliferation of UT7/EPO and HEL erythroleukemia cells and characterized the mechanism by which HLA-G5 influences erythropoietin receptor (EPOR) signaling. We show that HLA-G5 inhibits the proliferation of UT7/EPO cells, the EPOR signaling of which is similar to that of normal erythroid progenitors. HLA-G5-mediated inhibition was associated with reduced phosphorylation of JAK2 kinase and that of the downstream signaling proteins STAT-5 and STAT-3. Involvement of JAK2 in erythroid cell proliferation has been highlighted by the role of JAK2 V617F mutation in polycythemia vera (PV), a myeloproliferative disorder characterized by erythroid lineage overproduction. We demonstrate that HLA-G5 downregulates EPOR constitutive signaling of JAK2 V617F-expressing HEL cells, leading to inhibition of cell proliferation through G1 cell cycle arrest. Combination of HLA-G5 with JAK inhibitor I further decreases HEL cell growth. Clinical relevance is provided by analysis of PV patients who carry JAK2 V617F mutation, showing that HLA-G5 inhibits the formation of erythropoietin-independent erythroid colonies. Such HLA-G5-mediated inhibition constitutes a new parameter to be considered in the design of future approaches aimed at treating JAK2 V617F-positive myeloproliferative disorders.


Subject(s)
Erythropoiesis/physiology , HLA Antigens/physiology , Histocompatibility Antigens Class I/physiology , Polycythemia Vera/metabolism , Receptors, Erythropoietin/drug effects , Cell Division/drug effects , Cell Line, Tumor/drug effects , Cell Line, Tumor/metabolism , Colony-Forming Units Assay , Erythroid Precursor Cells/drug effects , Erythropoiesis/drug effects , Erythropoietin/physiology , G1 Phase/drug effects , HLA Antigens/blood , HLA Antigens/genetics , HLA Antigens/pharmacology , HLA-G Antigens , Histocompatibility Antigens Class I/blood , Histocompatibility Antigens Class I/genetics , Histocompatibility Antigens Class I/pharmacology , Humans , Janus Kinase 2/antagonists & inhibitors , Janus Kinase 2/genetics , Janus Kinase 2/metabolism , Leukemia, Erythroblastic, Acute/pathology , Microspheres , Mutation, Missense , Phosphorylation/drug effects , Point Mutation , Protein Processing, Post-Translational/drug effects , Receptors, Erythropoietin/physiology , Recombinant Fusion Proteins/pharmacology , STAT3 Transcription Factor/metabolism , STAT5 Transcription Factor/metabolism
11.
Tissue Antigens ; 69(3): 207-11, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17493143

ABSTRACT

Human leukocyte antigen (HLA)-G is a nonclassical HLA class I molecule from the major histocompatibility complex, which was initially shown to confer protection to the fetus from her mother's immune system. The Third International Conference on HLA-G, held in 2003, showed that beyond its role in fetal-maternal tolerance, HLA-G exerts tolerogenic functions involved in transplant acceptance as well as in tumoral and viral immune escape. The Fourth International Conference, which took place in Paris on July 2006, counted 72 oral presentations and about 200 attendees from 25 countries. The reports presented brought new insight into HLA-G research, and we summarize here the major advances on the HLA-G biology that were reported. Abstracts for all presentations can be found in volume 68 issue number 4 of Tissue Antigens.


Subject(s)
HLA Antigens/immunology , Histocompatibility Antigens Class I/immunology , Immune Tolerance/physiology , Pregnancy/immunology , Tumor Escape/immunology , Biomedical Research/trends , Female , HLA-G Antigens , Humans , Male
12.
Tissue Antigens ; 69 Suppl 1: 143-9, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17445190

ABSTRACT

In order to clarify the diagnostic relevance of soluble human leukocyte antigen-G (sHLA-G) molecules, reliable methods for the measurement of sHLA-G in various body fluids are of interest. Therefore, the aims of the 'Wet-Workshop for Quantification of Soluble HLA-G' held in Essen, Germany (at the Institute of Immunology, 18-20 October 2004) were to select and to validate HLA-G-specific enzyme-linked immunosorbent assay (ELISA) formats and purified standard HLA-G proteins, which can be easily generated and used as consensual references. We chose two ELISA formats, one for the simultaneous determination of shed HLA-G1 + sHLA-G5 (sHLA-G1 + G5) and one for the exclusive detection of HLA-G5 molecules. The first ELISA uses the antibody pair monoclonal antibody (mAb) MEM-G/9 + anti-beta2-microglobulin (beta2m), whereas the latter uses mAbs 5A6G7 + W6/32. Purified and well-defined HLA-G5 protein derived from insect SF9 cells transfected with HLA-G5 + human beta2m served as standard reagent. Twenty-five members of 13 international laboratories participated in the 3-day Wet-Workshop. The workshop demonstrated that the HLA-G5 protein was equally detected by both ELISA formats allowing direct comparison of quantitative results obtained by these two ELISA formats, and that sHLA-G1 + G5 and HLA-G5 molecules, respectively, were specifically and reproducibly quantified by the two ELISA formats. The comparison of the two ELISA results obtained allows the conclusion that sHLA-G1 and HLA-G5 molecules can exist in the blood of healthy donors. Moreover, there was evidence for a novel soluble HLA-G structure recognized by the mAbs 5A6G7 + W6/32 antibody combination but not by the one of mAb MEM-G/9 + anti-beta2m.


Subject(s)
HLA Antigens/blood , Histocompatibility Antigens Class I/blood , Plasma/metabolism , Serum/metabolism , Amniotic Fluid/chemistry , Antibodies, Monoclonal/immunology , Enzyme-Linked Immunosorbent Assay , Female , HLA Antigens/immunology , HLA-G Antigens , Histocompatibility Antigens Class I/immunology , Humans , Ovarian Neoplasms/blood , Ovarian Neoplasms/immunology , Plasma/immunology , Protein Isoforms , Serum/immunology , beta 2-Microglobulin/immunology , beta 2-Microglobulin/metabolism
13.
Cell Mol Life Sci ; 63(22): 2669-81, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17072500

ABSTRACT

HLA-G is expressed by tumors, in which it contributes to the evasion of immunosurveillance. NF-kappaB appears to be a candidate for regulating HLA-G expression, since it is considered to be a hallmark of cancer. We investigated the role of NF-kappaB in modulating HLA-G expression in HLA-G-positive tumor cells, JEG-3 (choriocarcinoma), FON (melanoma), and M8-HLA-G1 (HLAG1-transfected melanoma). The treatment of tumor cells with two NF-kappaB inducers, tumor necrosis factor-alpha and phorbol 12-myristate 13-acetate, decreased HLA-G1 cell surface expression but increased intracytoplasmic HLA-G proteins. Reduction in HLA-G1 cell surface expression is driven by NF-kappaB and involves a proteolytic shedding process dependent on metalloproteinase activity. In contrast, an increase in intracytoplasmic HLA-G proteins involves post-transcriptional mechanisms that are independent of NF-kappaB. These results, and the fact that soluble HLA-G1 reduces the cytotoxicity of the NKL cell line, lead us to propose a novel regulatory pathway for HLA-G expression by tumor cells that may have particular relevance in tumor escape.


Subject(s)
Choriocarcinoma/immunology , HLA Antigens/metabolism , Histocompatibility Antigens Class I/metabolism , Melanoma/immunology , NF-kappa B/metabolism , Tetradecanoylphorbol Acetate/pharmacology , Tumor Necrosis Factor-alpha/pharmacology , Cell Line , Cell Line, Tumor , Cell Membrane/immunology , Choriocarcinoma/genetics , Choriocarcinoma/metabolism , Coculture Techniques , Cytotoxicity, Immunologic , Gene Expression Regulation, Neoplastic , HLA Antigens/genetics , HLA Antigens/immunology , HLA-G Antigens , Histocompatibility Antigens Class I/genetics , Histocompatibility Antigens Class I/immunology , Humans , Immunologic Surveillance , Killer Cells, Natural/immunology , Melanoma/genetics , Melanoma/metabolism , Protein Modification, Translational/drug effects , Protein Processing, Post-Translational/drug effects , Tumor Escape
14.
Pathol Biol (Paris) ; 52(2): 97-103, 2004 Mar.
Article in French | MEDLINE | ID: mdl-15001239

ABSTRACT

The HLA-G molecule plays a crucial role in the protection of the fetus against aggression by the mother's immune system. Recently, it was shown that HLA-G was involved in the protection of the transplanted tissues, via the inhibition of all immune effectors that mediate graft rejection. The inhibitory functions of HLA-G were studied in vitro using allo- and xeno-geneic models, ex vivo on transplanted tissues biopsies, and in an in vivo animal model. In this review, we will summarize recent results which show that HLA-G acts as a regulator of immune function, seems to be directly involved in transplant acceptation, and should be taken into consideration when monitoring transplanted patients' status.


Subject(s)
HLA Antigens/immunology , Histocompatibility Antigens Class I/immunology , Transplantation Immunology , Animals , Antigen-Presenting Cells/immunology , CD4-Positive T-Lymphocytes/immunology , Fetus/immunology , Graft Survival/immunology , HLA Antigens/genetics , HLA-G Antigens , Histocompatibility Antigens Class I/genetics , Humans , Immune Tolerance/immunology , Killer Cells, Natural/immunology , Mice , Swine , T-Lymphocytes, Cytotoxic/immunology , Transfection , Transplantation, Heterologous , Transplantation, Homologous
15.
Tissue Antigens ; 62(4): 273-84, 2003 Oct.
Article in English | MEDLINE | ID: mdl-12974794

ABSTRACT

In 1998, the first International Conference on human leukocyte antigen-G (HLA-G) was held in Paris. At that time, HLA-G was still a new HLA class I molecule, few aspects of its immunological functions were known, and its expression by tumors was just being described. In 1998, tools to properly study HLA-G were lacking, especially monoclonal antibodies, and three conclusions were drawn after the congress: (i) animal models were needed, (ii) the biology of HLA-G isoforms had to be confirmed, and (iii) HLA-G expression by tumors required clarification. Five years later, these three issues have been addressed. HLA-G is now gaining pace and is investigated for its immuno-inhibitory functions in the context of multiple pathologies. Eighty five oral presentations were given this year for more than 200 investigators working on HLA-G by speakers from over 20 countries. The success of the 3rd International Conference on HLA-G reflects the interest and tremendous work of the many research teams which, over the years, contributed to the publication of more than 500 peer-review articles. We summarize the key points that were presented and discussed during this meeting.


Subject(s)
HLA Antigens/physiology , Histocompatibility Antigens Class I/physiology , Autoimmune Diseases/immunology , Central Nervous System Viral Diseases/complications , Central Nervous System Viral Diseases/immunology , Embryo, Mammalian/immunology , Female , HLA Antigens/chemistry , HLA Antigens/immunology , HLA-G Antigens , Histocompatibility Antigens Class I/chemistry , Histocompatibility Antigens Class I/immunology , Humans , Neoplasms/immunology , Pregnancy
16.
Nephrologie ; 24(8): 451-6, 2003.
Article in French | MEDLINE | ID: mdl-14737978

ABSTRACT

The Human Leucocyte Antigen-G (HLA-G) is a non-classical MHC class I molecule of low polymorphism, restricted tissue distribution and tolerogeneic functions. It is clearly demonstrated that HLA-G contributes to fetal graft tolerance by the maternal immune system. The tolerogeneic properties of HLA-G act via specific inhibitory receptors present on immunocompetents cells: HLA-G inhibits natural killer cells (NK) and CD8+ T cell cytotoxicity, suppresses CD4+ T cell proliferation in response to allogeneic stimulation and promotes T helper 2 (Th2) type responses. The soluble HLA-G protein is spontaneously secreted by allo-sensitized CD4+ T cells during mixed lymphocyte reactions (MLR), and inhibits their proliferative response. Finally, inhibition of dendritic cell maturation has been observed in HLA-G transgenic mice. In human organ transplantation, our group has reported in cardiac and liver-kidney transplanted patients, a positive correlation between the de novo ectopic expression of HLA-G in both patient's serum and graft biopsies, and a lower rate of acute rejection episodes of the grafts. Moreover no chronic graft rejection has been detected in those populations. These results support the involvement of HLA-G in regulatory mechanisms that may occur during human allotransplantation.


Subject(s)
HLA Antigens/metabolism , Heart Transplantation/immunology , Kidney Transplantation/immunology , Liver Transplantation/immunology , Cytokines/immunology , HLA Antigens/blood , Histocompatibility Antigens Class I/immunology , Humans , Immune Tolerance , Killer Cells, Natural/immunology , T-Lymphocytes/immunology , Transplantation, Homologous
17.
Cell Mol Life Sci ; 59(9): 1460-6, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12440768

ABSTRACT

Data are presented on the intracellular trafficking of HLA-G protein, taking the unique features of this non-classical molecule into consideration: the existence of seven isoforms resulting from alternative splicing (HLA-G1 to G7), and reduced tail length compared with HLA class I antigens. Biochemical studies and analysis of viral strategies for escaping the host immune system led to the demonstration that (i) both the membrane-bound (HLA-G1) and the soluble (HLA-G5) forms of the molecule require peptide association for cell surface expression, using TAP-dependent or TAP-independent pathways; (ii) peptide loading onto the HLA-G protein plays a critical role in controlling the quality of the molecule reaching the cell surface; (iii) surface expression of truncated HLA-G molecules is possible, and (iv) HLA-G expression may be restricted to soluble HLA-G5. These data reveal that HLA-G presents specific cell trafficking pathways and strongly support the contention that the primary function of HLA-G is as of an inhibitor ligand for immune-competent cells.


Subject(s)
HLA Antigens/metabolism , Histocompatibility Antigens Class I/metabolism , Protein Processing, Post-Translational , Protein Transport/physiology , ATP Binding Cassette Transporter, Subfamily B, Member 2 , ATP-Binding Cassette Transporters/metabolism , Animals , Gene Expression Regulation/immunology , Genes, MHC Class I , HLA Antigens/chemistry , HLA Antigens/genetics , HLA-G Antigens , Histocompatibility Antigens Class I/chemistry , Histocompatibility Antigens Class I/genetics , Humans , Protein Isoforms/chemistry , Protein Isoforms/genetics , Protein Isoforms/metabolism
18.
Pathol Biol (Paris) ; 50(1): 45-51, 2002 Feb.
Article in French | MEDLINE | ID: mdl-11873630

ABSTRACT

HLA-G is a low polymorphic non-classical major histocompatibility complex class I molecule which can be expressed upon seven isoforms, and whose expression is correlated to immune tolerance situations. Indeed, the expression of HLA-G may allow partially or non histocompatible cells to escape host's immune aimed to eliminate these "foreign" cells. Functions share by HLA-G molecules are the ability to inhibit lysis mediated by natural killer (NK) and by cytotoxic T cells, and to induce apoptosis of activated CD8+ T cells via the HLA-G soluble form. Such model which evades defenses of the immune system was described in the foeto-maternal symbiosis, in tumoral cells or histo-incompatible graft previously. The importance of the role of HLA-G molecules expressed by particular cells as a shield against immune defenses is actually largely studied. The control of HLA-G expression could be used as immunotherapeutic approach, either by up-modulating HLA-G expression in order to favour tolerance of incompatible cells such as foetal cell or graft, or by down-modulating HLA-G expression in order to support the destruction of tumoral cells by cytotoxic T cells. This article reports the recent data on polymorphism, HLA-G gene transcription and implication of HLA-G molecules in immune responses during pregnancy, transplantation or tumoral growth.


Subject(s)
HLA Antigens/immunology , Histocompatibility Antigens Class I/immunology , Immune Tolerance , CD8-Positive T-Lymphocytes/microbiology , HLA Antigens/genetics , HLA Antigens/physiology , HLA-G Antigens , Histocompatibility Antigens Class I/genetics , Histocompatibility Antigens Class I/physiology , Humans , Immunotherapy , Reference Values
19.
Proc Natl Acad Sci U S A ; 98(21): 12150-5, 2001 Oct 09.
Article in English | MEDLINE | ID: mdl-11572934

ABSTRACT

We recently reported that the nonclassical HLA class I molecule HLA-G was expressed in the endomyocardial biopsies and sera of 16% of heart transplant patients studied. The aim of the present report is to identify cells that may be responsible for HLA-G protein expression during the allogeneic reaction. Carrying out mixed lymphocyte cultures in which the responder cell population was depleted either in CD4(+) or CD8(+) T cells, we found that soluble HLA-G5 protein but not the membrane-bound HLA-G isoform was secreted by allo-specific CD4(+) T cells from the responder population, which suppressed the allogeneic proliferative T cell response. This inhibition may be reversed by adding the anti-HLA-G 87G antibody to a mixed lymphocyte culture. That may indicate a previously uncharacterized regulatory mechanism of CD4(+) T cell proliferative response.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , HLA Antigens/immunology , Histocompatibility Antigens Class I/immunology , Isoantigens/immunology , Apoptosis/immunology , Blotting, Western/methods , CD4-Positive T-Lymphocytes/metabolism , Cell Division , Flow Cytometry/methods , HLA Antigens/biosynthesis , HLA-G Antigens , Histocompatibility Antigens Class I/biosynthesis , Humans , Immunoenzyme Techniques , Isoantigens/biosynthesis , Lymphocyte Culture Test, Mixed , Protein Isoforms/biosynthesis , Protein Isoforms/immunology , Solubility , Subcellular Fractions
20.
Trends Immunol ; 22(10): 553-5, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11574278

ABSTRACT

Recent developments in the field of HLA-G research have revealed that, besides its involvement during pregnancy, HLA-G is expressed in peripheral tissues during pathological processes, such as viral infections, malignancies and organ transplantation. Here, we discuss recent findings regarding the influence of HLA-G on the T helper (Th) cytokine balance (favoring Th2-type responses), and the expression of HLA-G during chronic, cutaneous inflammatory diseases, such as psoriasis and atopic dermatitis. We propose a novel role for HLA-G as a tissue-protective molecule in inflammatory responses.


Subject(s)
HLA Antigens/immunology , Histocompatibility Antigens Class I/immunology , Cytokines/immunology , Female , HLA Antigens/biosynthesis , HLA-G Antigens , Histocompatibility Antigens Class I/biosynthesis , Humans , Pregnancy , Pregnancy Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...